This study is testing new treatments for patients with high-risk acute myeloid leukemia (AML), a type of cancer that affects blood and bone marrow. The study compares the usual treatment, which uses medicines called cytarabine and daunorubicin, to several new combinations. Some of these new treatments include medicines like venetoclax, azacitidine, and cytarabine liposome. Each medicine works by either stopping the growth of cancer cells or helping the body make normal blood cells. Patients in the study will receive one of these treatments and will be checked regularly with bone marrow tests and heart scans. The study will look at how well each treatment works and any side effects.

• The study lasts up to five years, with regular follow-ups.
• Participants will receive different treatments, some of which are experimental.
• Eligibility includes being between 18-59 years old and having specific health criteria.